News Agency
The Times

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

  • Written by PR Newswire
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Highlights

  • First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq.
  • Cohort 2 was recently completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq.
  • Data from...

Read more: First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Selecting Steel Plate for Industrial and Fabrication Projects

Start with the job requirements A successful fabrication project starts with material that suits the work it must perform. Choosing steel plate involves more than selecting a thickness from a stock list. Designers and procurement teams need to consider the load... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion